Sugi Predict

Sugi Predict / Compounds / SCHEMBL634159

SCHEMBL634159

SCHEMBL634159

CCC(=O)c1cc(F)cc(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 3/20 0.54
▸ CES1 P23141 3/20 0.54
▸ MAPT P10636 4/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ HCAR1 Q9BXC0 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ PTGS1 P23219 1/20 0.40
▸ DRD3 P35462 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ HTR7 P34969 1/20 0.39
▸ BRD4 O60885 1/20 0.39
▸ BAZ2B Q9UIF8 1/20 0.39
▸ BAZ2A Q9UIF9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15587366 0.87 CES2 (0.41) CES2CES1MAPTSMN1; SMN2L3MBTL1
SCHEMBL3716152 0.87 CES2 (0.41) CES2CES1MAPTSMN1; SMN2L3MBTL1
SCHEMBL30512212 0.86 TAS1R3 (0.43) CES2CES1MAPTSMN1; SMN2L3MBTL1
SCHEMBL12780435 0.86 TAS1R3 (0.43) CES2CES1MAPTSMN1; SMN2L3MBTL1
SCHEMBL8021523 0.84 SLC6A3 (0.45) CES2CES1MAPTSMN1; SMN2L3MBTL1
SCHEMBL19107523 0.82 CES2 (0.42) CES2CES1MAPTSMN1; SMN2L3MBTL1
SCHEMBL27824440 0.82 CES2 (0.38) CES2CES1MAPTSMN1; SMN2L3MBTL1
SCHEMBL6925102 0.82 CES2 (0.47) CES2CES1ALDH1A1PPARGPPARA
SCHEMBL5565349 0.82 CES2 (0.50) CES2CES1MAPTSMN1; SMN2L3MBTL1
SCHEMBL11382828 0.82 MAPT (0.50) MAPTSMN1; SMN2L3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326766-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2025-10-23 — — US disclosed
EP-4526300-A1 RIPK1 INHIBITORS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2025-03-26 — — EP disclosed
US-20240025912-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2024-01-25 — — US disclosed
US-20240025912-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2024-01-25 — — US disclosed
US-20240025912-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2024-01-25 — — US disclosed
WO-2023225041-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2023-11-23 — — WO disclosed
WO-2023225041-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2023-11-23 — — WO disclosed
CN-111212830-B N- (substituted sulfonyl) benzamide derivative and preparation method and medical application thereof 浙江海正药业股份有限公司 2023-07-04 — — CN disclosed
CN-115650830-A Method for preparing alpha-substituted methyl ketone from terminal olefin 长沙资材科技有限公司 2023-01-31 — — CN disclosed
US-10919841-B2 Monoamine reuptake inhibitors RESEARCH TRIANGLE INSTITUTE (US) 2021-02-16 — — US disclosed
WO-1999040091-A1 BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS AMGEN INC. (US) 1999-08-12 — — WO disclosed
EP-0788490-A1 BISARYLCARBINOL CINNAMIC ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC. (CA) 1997-08-13 — — EP disclosed
EP-0788497-A1 BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC. (CA) 1997-08-13 — — EP disclosed
US-5552437-A ANTIASTHMATIC, ANTIALLERGIC, ANTIINFLAMMATORY, AND CYTOPROTECTIVE AGENTS MERCK FROSST CANADA, INC. (CA) 1996-09-03 — — US disclosed
US-5527827-A ANTIASTHMATIC, ANTIALLERGIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS MERCK FROSST CANADA, INC. (CA) 1996-06-18 — — US disclosed
WO-1996013491-A1 BISARYLCARBINOL CINNAMIC ACIDS AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC. (CA) 1996-05-09 — — WO disclosed
WO-1996013500-A1 BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC. (CA) 1996-05-09 — — WO disclosed
EP-0426416-B1 Novel morpholinol compounds, their preparation and use WELLCOME FOUND (GB) 1994-02-16 — — EP disclosed
US-5104870-A Psychological disorders BURROUGHS WELLCOME CO. (US) 1992-04-14 — — US disclosed
EP-0426416-A1 Novel morpholinol compounds, their preparation and use THE WELLCOME FOUNDATION LIMITED (GB) 1991-05-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025912-A1 RIPK1 INHIBITORS AND METHODS OF USE RIPK1, RIPK2, RIPK3 CES2 4320/4885CES1 1896/4885MAPT 2642/4885
US-10919841-B2 Monoamine reuptake inhibitors SLC6A2, SLC6A4, SLC6A3 CES2 100/4885CES1 577/4885MAPT 440/4885
US-20250326766-A1 RIPK1 INHIBITORS AND METHODS OF USE RIPK1, RIPK2, RIPK3 CES2 4256/4885CES1 1435/4885MAPT 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.